Theravance Biopharma (FRA:0TB) Cyclically Adjusted Book per Share: €1.22 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:0TB Theravance Biopharma Inc FRA:0TB
72 GF Score
Price €14.60
GF Value €16.18
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Theravance Biopharma Cyclically Adjusted Book per Share?

Theravance Biopharma FRA:0TB -0.68% 72 Cyclically Adjusted Book per Share is €1.22 as of Mar. 2026. GuruFocus rates FRA:0TB with a GF Score™ of 72/100 and a GF Value™ of €16.18 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Theravance Biopharma's adjusted book value per share for the three months ended in Mar. 2026 was €4.879. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1.22 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Theravance Biopharma's average Cyclically Adjusted Book Growth Rate was -18.50% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -10.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Theravance Biopharma was -10.60% per year. The lowest was -10.60% per year. And the median was -10.60% per year.

As of today (2026-07-30), Theravance Biopharma's current stock price is €14.60. Theravance Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €1.22. Theravance Biopharma's Cyclically Adjusted PB Ratio of today is 11.97.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Theravance Biopharma was 13.39. The lowest was 3.03. And the median was 4.68.


Theravance Biopharma  (FRA:0TB) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Theravance Biopharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=14.60/1.22
=11.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Theravance Biopharma was 13.39. The lowest was 3.03. And the median was 4.68.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Theravance Biopharma Cyclically Adjusted Book per Share Related Terms


Theravance Biopharma Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Theravance Biopharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theravance Biopharma Cyclically Adjusted Book per Share Chart

Theravance Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 1.98 2.34 1.95 1.28

Theravance Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.73 1.50 1.35 1.28 1.22

FRA:0TB vs ABUS, SANA, ANNX: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Theravance Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theravance Biopharma Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Theravance Biopharma's Cyclically Adjusted PB Ratio falls into.


FRA:0TB
72GF Score
Theravance Biopharma Inc FRA:0TB
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theravance Biopharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Theravance Biopharma's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.879/330.2130*330.2130
=4.879

Current CPI (Mar. 2026) = 330.2130.

Theravance Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201606 5.981 241.018 8.194
201609 5.519 241.428 7.549
201612 6.284 241.432 8.595
201703 5.157 243.801 6.985
201706 3.987 244.955 5.375
201709 2.856 246.819 3.821
201712 1.790 246.524 2.398
201803 0.938 249.554 1.241
201806 0.534 251.989 0.700
201809 -0.208 252.439 -0.272
201812 -0.814 251.233 -1.070
201903 -1.786 254.202 -2.320
201906 -2.144 256.143 -2.764
201909 -2.924 256.759 -3.761
201912 -3.533 256.974 -4.540
202003 -2.269 258.115 -2.903
202006 -2.829 257.797 -3.624
202009 -3.472 260.280 -4.405
202012 -3.881 260.474 -4.920
202103 -4.807 264.877 -5.993
202106 -3.393 271.696 -4.124
202109 -3.732 274.310 -4.493
202112 -4.025 278.802 -4.767
202203 -4.194 287.504 -4.817
202206 -4.330 296.311 -4.825
202209 7.205 296.808 8.016
202212 6.394 296.797 7.114
202303 5.717 301.836 6.254
202306 4.816 305.109 5.212
202309 4.538 307.789 4.869
202312 4.061 306.746 4.372
202403 3.881 312.332 4.103
202406 3.678 314.175 3.866
202409 3.402 315.301 3.563
202412 3.389 315.605 3.546
202503 3.071 319.799 3.171
202506 3.871 322.561 3.963
202509 3.912 324.800 3.977
202512 4.962 324.054 5.056
202603 4.879 330.213 4.879

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €1.22 mean?
Theravance Biopharma (FRA:0TB) has a Cyclically Adjusted Book per Share of €1.22 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Theravance Biopharma and its competitors.
Is Theravance Biopharma's Cyclically Adjusted Book per Share too high?
Theravance Biopharma's current Cyclically Adjusted Book per Share is €1.22. Overall, Theravance Biopharma has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Theravance Biopharma's Cyclically Adjusted Book per Share compare to ABUS and SANA?
Theravance Biopharma's Cyclically Adjusted Book per Share of €1.22 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Theravance Biopharma and its competitors. Theravance Biopharma's current Cyclically Adjusted Book per Share is €1.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theravance Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Theravance Biopharma (FRA:0TB) is currently considered Modestly Undervalued. The stock's GF Value™ is €16.18, compared to a current price of €14.60 — trading 9.8% below its estimated fair value. The current Cyclically Adjusted Book per Share is €1.22. Theravance Biopharma's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Theravance Biopharma (FRA:0TB), the current Cyclically Adjusted Book per Share is €1.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Theravance Biopharma (FRA:0TB) Overvalued in 2026?

Based on GuruFocus' analysis, Theravance Biopharma stock appears to be undervalued. The current stock price of €14.60 is trading 9.8% below its estimated GF Value™ of €16.18. GuruFocus considers Theravance Biopharma to be Modestly Undervalued.

Key valuation signals for FRA:0TB:

  • Cyclically Adjusted Book per Share: €1.22
  • GF Value™: €16.18 vs. price of €14.60 (9.8% below fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the FRA:0TB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Theravance Biopharma Business Description

Other Exchanges TBPH:USA
Address C/O Theravance Biopharma US, LLC, 901 Gateway Boulevard, South San Francisco, CA, USA, 94080
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
72GF Score

Get the complete analysis for FRA:0TB

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.60
Price
€16.18
GF Value